Dr John McHutchinson steps down from Gilead with $1.1 million goodbye

pharmafile | July 18, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Gilead has said that Dr John McHutchison is stepping down after nine years at the firm.

Gilead’s Chief Scientific Officer and Head of Research and Development has decided to leave the company next month, Gilead said.

Under McHutchinson, Gilead developed five new hepatitis drugs, which have been used by as many as 3.2 million people around the world.

McHutchinson, who joined Gilead in 2010, also oversaw the Foster City firm’s move into oncology in leading development of cancer drug Zydelig (idelalisib). McHutchinson was promoted to Chief Scientific Officer in March 2018.

“Over the past nine years, John’s scientific contributions and leadership have played an instrumental role in shaping our research efforts and in improving care for millions of patients with life-threatening illnesses,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead.

“Under his guidance, the company was able to rapidly advance our hepatitis C portfolio, enabling therapies to reach people in need at an unprecedented pace, and he has continued to build on that work by helping the company expand its therapeutic areas of focus. We are grateful to John for his many contributions and wish him the best.”

On leaving the firm, McHutchinson will receive a cheque for $1.1 million. “The Company will pay Dr. McHutchison a lump sum payment of $1,100,000” a Gilead SEC filing said.

McHutchinson’s ‘decision’ comes amid a shake-up in the firm as both Gilead’s Chief Patent Officer Gregg Alton and the company’s human resources chief Katie Watson said they would leave.

Related Content

No items found

Latest content